LLY Stock Recent News

I track a universe of 50 high-quality dividend growth stocks to identify attractive investment opportunities based on valuation and future return potential. My custom valuation model highlights 23 stocks with estimated future returns above 10%, with 12 of these also appearing undervalued by free cash flow. Top picks include Resmed, MarketAxess, Ferrari, MSCI, Accenture, and others, each offering strong return estimates and solid business fundamentals.

Novo Nordisk stands out as the best pharma stock, outperforming Eli Lilly in key areas. Novo's higher profitability, stronger cash flow, and much lower valuation make it a more attractive investment than Lilly. Novo's discount could become a premium, as investors seek to diversify away from US stocks.

Eli Lilly and Company (NYSE:LLY ) 2025 Wells Fargo Healthcare Conference September 5, 2025 9:30 AM EDT Company Participants Patrik Jonsson - Executive VP & President of Lilly International Mike Czapar - Director of Investor Relations Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Good morning. Thank you very much for being here on a Friday.

Eli Lilly (LLY 0.56%) is typically a market outperformer, but it has had a challenging year so far. Besides general market volatility, the company has dealt with clinical setbacks, lower-than-expected guidance, and the threat of tariffs.

While many dividend stocks are viewed as slow-growing investments, this isn't always the case. Right now, investment bank analysts up and down Wall Street are bullish for a pair of dividend-paying stocks they think could deliver a return above 20% over the next 12 months.

Biotech Company Introduces Protein Therapeutics Platforms to Combat Cancer and Non-Oncology Diseases Biotech Company Introduces Protein Therapeutics Platforms to Combat Cancer and Non-Oncology Diseases

The Breakthrough Therapy designation for olomorasib is based on data from the Phase 1/2 LOXO-RAS-20001 trial and Phase 3 SUNRAY-01 trial Updated efficacy and safety data for olomorasib will be presented at the IASLC 2025 World Conference on Lung Cancer INDIANAPOLIS , Sept. 4, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib, in combination with anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the first-line treatment of patients with unresectable advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 expression ≥ 50%, as determined by FDA approved tests.

Eli Lilly (LLY 0.15%) stock has soared in the triple digits over the past three years thanks to one particular product line: its weight-loss drugs. Lilly is the maker of tirzepatide, sold under the name Mounjaro for type 2 diabetes and Zepbound for weight loss.

I am bullish on Eli Lilly, despite recent underperformance and Orforglipron's clinical results falling short of high expectations. Eli Lilly's robust R&D, strong pipeline, and leadership in diabetes, obesity, and oncology underpin its long-term growth prospects. Recent financial results exceeded expectations, with raised guidance and continued market share gains in weight loss therapies, supporting valuation upside.

Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.